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Abstract
Fibroblast growth factor (FGF) 23, a circulating 26-kDa peptide produced by osteogenic cells, is a novel
phosphaturic factor. In our previous study, binge-eating/purging type anorexia nervosa (AN-BP) patients had
elevated plasma intact FGF23 (iFGF23) levels, while restricting type (AN-R) patients had plasma iFGF23 levels similar
to healthy controls. Although bulimia nervosa (BN) patients as well as some patients with AN-BP regularly engage
in binge eating, there have been no studies regarding plasma iFGF23 levels in BN patients. Therefore, this study
was performed to determine plasma iFGF23 concentrations in BN patients and healthy controls. The study
population consisted of 13 female BN patients and 11 healthy female controls. Blood samples were collected from
all subjects after overnight fasting. Plasma iFGF23 was measured using an ELISA kit in a cross-sectional manner. The
two-tailed Mann-Whitney U-test was used to assess differences between BN patients and healthy controls. In
addition, BN patients were divided into two groups based on questionnaire-reported binge eating frequency
immediately prior to participation in this study: high frequency of binge eating (once a week or more; HF group;
n = 8) and low frequency of binge eating (less than once a week; LF group; n = 5). Two-tailed Mann-Whitney U-
test with Bonferroni’s correction was performed after the Kruskal-Wallis test to assess differences between HF
group, LF group, and healthy controls. Median (quartiles) plasma iFGF23 levels were greater in BN patients (35.5
[14.8-65.0] pg/ml) than in controls (3.8 [not detected-5.3] pg/ml; p = 0.002). In addition, median (quartiles) plasma
iFGF23 levels were greater in the HF group (62.3 [44.4-73.4] pg/ml) than in controls (p < 0.001) and in the LF
group (12.9 [not detected-30.3] pg/ml; p = 0.011), while there were no differences between the LF group and
controls (p = 0.441). This is the first study to show that BN patients have elevated plasma iFGF23 levels. Moreover,
this study showed that BN patients with a high frequency of binge eating have elevated plasma iFGF23 levels,
while iFGF23 levels are similar to healthy controls in those with a low frequency of binge eating. Plasma iFGF23
level may be a suitable indicator of binge eating in BN patients.
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D (1,25-(OH)2D)
Findings
Fibroblast growth factor (FGF) 23, a circulating 26-kDa
peptide produced by osteogenic cells, is a novel phospha-
turic factor, which is important for the regulation of inor-
ganic phosphate homeostasis and for vitamin D
metabolism [1]. FGF23 inhibits renal proximal tubule
phosphate reabsorption, increases renal phosphate excre-
tion, and reduces serum phosphate without affecting
serum calcium. FGF23 also strongly suppresses 1,25-
dihydroxyvitamin D (1,25-(OH)2D) production [2,3].
Circulating FGF23 levels are regulated by serum phos-
phate [4,5], 1,25-(OH)2D [3,6] and dietary phosphate
[6]. Dietary phosphate plays an important role in FGF23
regulation, and dietary phosphate loading increases cir-
culating FGF23 levels in healthy men in a matter of
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1,25-(OH)2D levels [8].
Bulimia nervosa (BN) is an eating disorder characterized
by habitual binge eating, inappropriate compensatory
behaviors, such as self-induced vomiting, a preoccupation
with body weight, and excessive self-evaluation of weight
and shape. For BN, the Diagnostic and Statistical Manual
of Mental Disorders-Fourth Edition (DSM-IV) specifies
that binging and compensatory behaviors must occur with
a minimum average frequency and duration of at least
twice a week for three months [9].
Our previous study showed that binge-eating/purging
type anorexia nervosa (AN-BP) patients had elevated
plasma intact FGF23 (iFGF23) levels, while restricting type
(AN-R) patients had plasma iFGF23 levels similar to
healthy controls [10]. Although BN patients as well as
some patients with AN-BP regularly engage in binge eat-
ing, there have been no previous studies regarding plasma
iFGF23 levels in BN patients. Therefore, the present study
was performed to determine plasma iFGF23 concentra-
tions in BN patients and healthy controls.
The study population consisted of 13 female outpatients
of The University of Tokyo Hospital diagnosed with pur-
ging type BN according to DSM-IV by experienced clini-
cians, and 11 healthy female controls. All of the patients
had binge eating episodes at least twice a week on average
within the last three months, while the frequencies of
binge eating episodes in some of the patients were small
within the last two to four weeks just before the study
because they were undergoing treatment. In addition, BN
patients were divided into two groups on the basis of
questionnaire-reported binge eating frequency just prior
to participation in this study: patients with high frequency
of binge eating (once a week or more; HF group; n =8 )
and patients with low frequency of binge eating (less than
once a week; LF group; n = 5). Physical comorbidity and
medication directly affecting calcium and phosphate meta-
bolism at the time of enrollment in this study were exclu-
sionary criteria.
Blood samples were collected from all participants after
overnight fasting. All BN patients completed a question-
naire about frequency of binge eating and vomiting for
two weeks to one month just prior to participation in this
study. Frequency of binge eating was rated on a six-point
scale as follows: “hardly ever,”“ once a month,”“ once a
week,”“ two or three times a week,”“ daily,” and “two or
three times a day.” Frequency of vomiting was rated on a
seven-point scale as follows: “never,”“ occasionally,”“ once
aw e e k , ”“ two or three times a week,”“ daily,”“ two or three
times a day,” and “more than four times a day.” The proto-
col was approved by the Institutional Ethics Committee of
the University of Tokyo, and written informed consent
was obtained from all subjects prior to enrollment in the
study.
All blood samples were drawn into chilled tubes con-
taining EDTA-2Na (1 mg/ml) and were then immediately
centrifuged at 4°C. Plasma portions were stored at -70°C
prior to analysis. Plasma concentrations of iFGF23 were
measured using an ELISA kit (Immutopics, San Clemente,
CA) [10-12], with a sensitivity of 1.0 pg/ml, intraassay
variability of <4.4%, and interassay variability of <6.5%. All
samples were analyzed in duplicate. Plasma 1,25-(OH)2D
and 25-hydroxyvitamin D (25-OHD) concentrations were
measured by RIA (SRL, Tokyo, Japan). Plasma calcium,
phosphate, and intact parathyroid hormone (iPTH) con-
centrations were measured using standard laboratory
methods (SRL).
The two-tailed Mann-Whitney U-test was used to assess
the significance of differences between BN patients and
healthy controls. The two-tailed Mann-Whitney U-test
with Bonferroni’s correction was performed after the
Kruskal-Wallis test to assess the significance of differences
between the HF group, LF group, and healthy controls.
Values of p < 0.05 were considered significant, except that
p < 0.017 was considered significant in the two-tailed
Mann-Whitney U-test with Bonferroni’s correction. Spear-
man’s rank-correlation coefficients (r) were used to assess
the relationship between plasma iFGF23 levels and plasma
phosphate or 1,25-(OH)2D levels for BN patients. All sta-
tistical calculations were performed using SPSS for Win-
dows version 10.0 (SPSS, Chicago, IL). All data are
presented as the median, first quartile, and third quartile.
Clinical profiles and biochemical data are summarized in
Table 1. Median (quartiles) plasma iFGF23 levels were sig-
nificantly greater in all BN patients (35.5 [14.8-65.0] pg/
ml) than in controls (3.8 [not detected-5.3] pg/ml; p =
0.002). In addition, median (quartiles) plasma iFGF23
levels were significantly greater in the HF group (62.3
[44.4-73.4] pg/ml) than in healthy controls (p < 0.001;
Figure 1) or the LF group (12.9 [not detected-30.3] pg/ml;
p = 0.011; Figure 1), while there were no significant differ-
ences between the LF group and healthy controls (p =
0.441; Figure 1). Binge eating behavior was significantly
more frequent in the HF group than in the LF group (p =
0.002), while there were no differences in frequency
of vomiting between the HF group and the LF group
(p = 0.222).
For all BN patients, iFGF23 levels were correlated with
neither plasma phosphate levels (r =0 . 1 6 0 ,p=0 . 6 0 2 )
nor plasma 1,25-(OH)2D levels (r = 0.132, p = 0.667).
This is the first study to show that BN patients have
elevated plasma iFGF23 levels. Moreover, the present
study showed that BN patients with a high frequency of
binge eating have elevated plasma iFGF23 levels, while
the iFGF23 levels are similar to healthy controls in
those with a low frequency of binge eating. These
results suggest that plasma iFGF23 levels may be asso-
ciated with binge eating frequency in BN patients.
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increased serum amylase levels in BN patients. The
serum amylase level is an established indicator of vomit-
ing behavior. However, there are no established indica-
tors of binge eating behavior. The establishment of an
indicator of binge eating in BN patients would be thera-
peutically useful. Plasma iFGF23 level may be a suitable
indicator of binge eating behavior in BN patients.
During binge eating, BN patients eat a large quantity of
food at once, including foods such as chocolates, cakes,
snacks, and sweet buns, which generally contain moderate
to large amounts of phosphate. Thus, binge eating in BN
patients may be regarded as dietary phosphate loading. It
is speculated that dietary phosphate loading with binge
eating may increase plasma iFGF23 levels in BN patients.
The present study showed that there were no significant
differences in plasma calcium, phosphate, iPTH, 1,25-
(OH)2D, or 25-OHD levels between the three groups.
These results were consistent with the speculation.
The present study had three limitations. First, the num-
ber of BN patients was small. Second, the volumes of
binge eating and purging in the BN patients prior to par-
ticipation in the study were not available. Third, dietary
phosphate intake prior to participation in the study was
not assessed in BN patients. We were therefore unable to
completely assess the relationships between binge eating
behavior, dietary phosphate intake, and plasma iFGF23
levels. In future studies, dietary phosphate intake and the
volume of binge eating prior to participation in the study
should be determined in addition to plasma iFGF23,
1,25-(OH)2D, and 25-OHD levels.
This preliminary study showed that BN patients have
elevated plasma iFGF23 levels, and that BN patients
with a high frequency of binge eating have elevated
plasma iFGF23 levels, while iFGF23 levels are similar to
healthy controls in those with a low frequency of binge
eating. Plasma iFGF23 level may be a suitable indicator
of binge eating in BN patients.
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Table 1 Clinical profiles and biochemical data of women with bulimia nervosa and healthy controls
BN patients with high frequency of
binge eating (n = 8)
BN patients with low frequency of
binge eating (n = 5)
Controls
(n = 11)
Normal
values
p
Body Mass Index (kg/m
2) 19.9 (18.4-22.0) 18.6 (18.2-18.6) 19.7 (19.5-
21.8)
0.103
Age (years) 28 (25-28) 25 (23-27) 27 (21-29) 0.792
age at the time of disease
onset (years)
19 (18-21) 19 (18-20)
disease duration (years) 5.8 (4.0-9.8) 6.0 (3.5-9.0)
frequency of binge eating 2-3/week (2-3/week-1/day)* 1/month (1/month-1/month)
frequency of vomiting 2-3/week (occasionally-1/day) occasionally (occasionally-occasionally)
uncorrected Ca (mg/dl) 8.8 (8.7-9.3) 9.4 (9.2-9.7) 8.9 (8.7-9.1) 8.5-10.2 0.204
P (mg/dl) 3.6 (2.9-4.1) 3.5 (2.9-3.6) 2.9 (2.5-3.2) 2.4-4.3 0.133
intact PTH (pg/ml) 62 (43-69) 54 (45-55) 38 (33-45) 10-65 0.073
1,25-(OH)2D (pg/ml) 39.4 (17.1-55.6) 38.2 (37.7-42.9) 39.7 (20.9-
47.5)
20.0-60.0 0.837
25-OHD (ng/ml) 15 (13-16) 18 (17-19) 20 (15-21) 7-41 0.186
All values are shown as the median (first quartile-third quartile). The p-values in the rightmost column were calculated using the Kruskal-Wallis test.
* p < 0.05 vs. BN patients with low frequency of binge eating (two-tailed Mann-Whitney U-test).
BN; bulimia nervosa. PTH; parathyroid hormone. 1,25-(OH)2D; 1,25-dihydroxyvitamin D. 25-OHD; 25-hydroxyvitamin D.
Figure 1 Dot plots of plasma intact fibroblast growth factor 23
(iFGF23) levels in bulimia nervosa (BN) patients with a high
frequency of binge eating (HF group), BN patients with a low
frequency of binge eating (LF group), and healthy controls. The
graphs show median values (bars). The two-tailed Mann-Whitney U-
test with Bonferroni’s correction was used to assess the significance
of differences among groups. A value of p < 0.017 was considered
statistically significant. *p < 0.017 vs. LF group. **p < 0.001 vs.
controls.
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